Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   MIDDLE EAST JOURNAL OF DIGESTIVE DISEASES (MEJDD)   JULY 2016 , Volume 8 , Number 3; Page(s) 241 To 247.
 
Paper: 

A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL

 
 
Author(s):  ALHOOEI SAMAN, TIRGAR FAKHERI HAFEZ*, HOSSEINI VAHID, MALEKI IRADJ, TAGHVAEI TARANG, VALIZADEH SEYED MOHAMMAD, BARI ZOHRE
 
* DEPARTMENT OF GASTROENTEROLOGY, GUT AND LIVER RESEARCH CENTER, MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES, SARI, IRAN
 
Abstract: 

BACKGROUND: Helicobacter pylori (H. pylori)is one of the most common bacterial infections worldwide. We designed a study to compare the efficacy of 14-day hybrid regimen with 10-day concomitant therapy forH. pylori eradication in Iran.
METHODS 252 patients with naïveH. pylori infection were randomly divided to receive either hybrid regimen (pantoprazole 40 mg, and amoxicillin 1 gr twice daily for 14 days, accompanied by clarithromycin 500 mg, and metronidazole 500 mg, twice daily just during the last 7 days) or concomitant regimen (pantoprazole 40 mg, amoxicillin 1 gr, clarithromycin 500 mg, and metronidazole 500 mg, all twice daily for 10 days).
8 weeks after therapy, 14C- urease breath test was performed to confirm eradication.
RESULTS: According to intention to treat analysis, the eradication rates were 87.3% (95% CI: 81.4–93.1) and 80.9% (95% CI: 74-87.8) in hybrid and concomitant groups, respectively (p=0.38). Per-protocol eradication rates were 89.3% (95% CI: 83.8-94.7) and 83.1% (95% CI: 76.3-89.8), respectively (p=0.19). The rates of severe side effects were not statistically different between the two groups (4% vs.8.7%).
CONCLUSION: 14-day hybrid therapy can be considered as a nearly acceptable regimen with few severe side effects in Iran. However, it seems that the efficacy of this therapy is decreasing as the resistance rates to antibiotics are increasing. We suggest further studies to assess the efficacy of a more prolonged concomitant therapy forH. pylori eradication in Iran.

 
Keyword(s): 
 
 
References: 
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

ALHOOEI, S., & TIRGAR FAKHERI, H., & HOSSEINI, V., & MALEKI, I., & TAGHVAEI, T., & VALIZADEH, S., & BARI, Z. (2016). A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL. MIDDLE EAST JOURNAL OF DIGESTIVE DISEASES (MEJDD), 8(3), 241-247. https://www.sid.ir/en/journal/ViewPaper.aspx?id=511082



Vancouver: Copy

ALHOOEI SAMAN, TIRGAR FAKHERI HAFEZ, HOSSEINI VAHID, MALEKI IRADJ, TAGHVAEI TARANG, VALIZADEH SEYED MOHAMMAD, BARI ZOHRE. A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL. MIDDLE EAST JOURNAL OF DIGESTIVE DISEASES (MEJDD). 2016 [cited 2021July24];8(3):241-247. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=511082



IEEE: Copy

ALHOOEI, S., TIRGAR FAKHERI, H., HOSSEINI, V., MALEKI, I., TAGHVAEI, T., VALIZADEH, S., BARI, Z., 2016. A COMPARISON BETWEEN HYBRID AND CONCOMITANT REGIMENS FOR HELICOBACTER PYLORI ERADICATION: A RANDOMIZED CLINICAL TRIAL. MIDDLE EAST JOURNAL OF DIGESTIVE DISEASES (MEJDD), [online] 8(3), pp.241-247. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=511082.



 
  pdf-File
Yearly Visit 45
 
 
Latest on Blog
Enter SID Blog